Invention Grant
US08951998B2 Quinoxaline-containing compounds as hepatitis C virus inhibitors
有权
含喹喔啉的化合物作为丙型肝炎病毒抑制剂
- Patent Title: Quinoxaline-containing compounds as hepatitis C virus inhibitors
- Patent Title (中): 含喹喔啉的化合物作为丙型肝炎病毒抑制剂
-
Application No.: US13657555Application Date: 2012-10-22
-
Publication No.: US08951998B2Publication Date: 2015-02-10
- Inventor: Yonghua Gai , Yat Sun Or , Zhe Wang
- Applicant: Enanta Pharmaceuticals, Inc.
- Applicant Address: US MA Watertown
- Assignee: Enanta Pharmaceuticals, Inc.
- Current Assignee: Enanta Pharmaceuticals, Inc.
- Current Assignee Address: US MA Watertown
- Agency: Edwards Wildman Palmer LLP
- Agent Jeffery D. Hsi; Stephen W. Rafferty
- Main IPC: A61K31/33
- IPC: A61K31/33 ; C07D487/00 ; C07D498/12 ; C07D498/18 ; C07K5/10 ; C07D498/22 ; C07K5/08 ; C07K5/113
Abstract:
The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Public/Granted literature
- US20130144036A1 QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS Public/Granted day:2013-06-06
Information query
